Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cetuximab and Radiotherapy in Laryngeal Preservation

Cetuximab and Radiotherapy in Laryngeal Preservation Letters Corresponding Author: Glenn E. Green, MD, Division of Pediatric Second, in the article by Bonner et al, tumor and node Otolaryngology, Department of Otolaryngology–Head & Neck Surgery, stages are more advanced in the radiotherapy alone (RT) group University of Michigan, 1540 E Hospital Dr, SPC 5-702, Ann Arbor, MI than in the cetuximab plus radiotherapy (CRT) group (the fre- (gegreen@med.umich.edu). quency of T4 stage is 35.9% in RT group and 27.8% in the CRT Published Online: January 26, 2017. doi:10.1001/jamaoto.2016.3932 group, while the frequency of N2-3 stages is 51.3% and 45.6% Author Contributions: Dr Green had full access to all of the data in the study and in the 2 groups, respectively). This is an important bias since takes responsibility for the integrity of the data and accuracy of data analysis. Concept and design: Morrison, Flanagan, Hollister, Green. T4 and N2-3 stages are the major determinants of tumor lo- Acquisition, analysis, or interpretation of data: Morrison, Sengupta, Ohye, 2 coregional control. Considering the difference in laryngeal Hollister, Green. preservation (LP) rates between RT and CRT groups is Drafting of the manuscript: Morrison, Sengupta, Ohye. “encouraging” but not statistically significant in Bonner and Critical revision of the manuscript for http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Otolaryngology - Head & Neck Surgery American Medical Association

Cetuximab and Radiotherapy in Laryngeal Preservation

Loading next page...
 
/lp/american-medical-association/cetuximab-and-radiotherapy-in-laryngeal-preservation-Q14qc6PfY0
Publisher
American Medical Association
Copyright
Copyright 2016 American Medical Association. All Rights Reserved.
ISSN
2168-6181
eISSN
2168-619X
DOI
10.1001/jamaoto.2016.3821
pmid
28006053
Publisher site
See Article on Publisher Site

Abstract

Letters Corresponding Author: Glenn E. Green, MD, Division of Pediatric Second, in the article by Bonner et al, tumor and node Otolaryngology, Department of Otolaryngology–Head & Neck Surgery, stages are more advanced in the radiotherapy alone (RT) group University of Michigan, 1540 E Hospital Dr, SPC 5-702, Ann Arbor, MI than in the cetuximab plus radiotherapy (CRT) group (the fre- (gegreen@med.umich.edu). quency of T4 stage is 35.9% in RT group and 27.8% in the CRT Published Online: January 26, 2017. doi:10.1001/jamaoto.2016.3932 group, while the frequency of N2-3 stages is 51.3% and 45.6% Author Contributions: Dr Green had full access to all of the data in the study and in the 2 groups, respectively). This is an important bias since takes responsibility for the integrity of the data and accuracy of data analysis. Concept and design: Morrison, Flanagan, Hollister, Green. T4 and N2-3 stages are the major determinants of tumor lo- Acquisition, analysis, or interpretation of data: Morrison, Sengupta, Ohye, 2 coregional control. Considering the difference in laryngeal Hollister, Green. preservation (LP) rates between RT and CRT groups is Drafting of the manuscript: Morrison, Sengupta, Ohye. “encouraging” but not statistically significant in Bonner and Critical revision of the manuscript for

Journal

JAMA Otolaryngology - Head & Neck SurgeryAmerican Medical Association

Published: May 22, 2017

References